CRP apheresis added to usual care for cardiogenic shock after a heart attack
Tests removing C-reactive protein from the blood in cardiogenic shock after heart attack.
Plain-language title generated from the registry record
Registry title: CRP Apheresis in Infarct-Related Cardiogenic Shock
Key facts
- Where
- Leipzig, GermanySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07687017, who can take part
Where in Germany
- Heart Center Leipzig at University of LeipzigLeipzig, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Leipzig Heart Science gGmbH
- Trial code
- NCT07687017
- Record updated
- 27 October 2026
- Original description
Cardiogenic shock complicating acute myocardial infarction remains associated with high short-term mortality despite guideline-directed therapy. Systemic inflammation, particularly elevated C-reactive protein (CRP), may contribute to ongoing myocardial injury and organ dysfunction.Read full original descriptionShow less
Selective C-Reactive Protein Apheresis in Cardiogenic Shock Complicating Acute Myocardial Infarction (CRP-SHOCK Trial)
Cardiogenic shock complicating acute myocardial infarction remains associated with high short-term mortality despite guideline-directed therapy. Systemic inflammation, particularly elevated C-reactive protein (CRP), may contribute to ongoing myocardial injury and organ dysfunction.
The CRP-SHOCK trial is an investigator-initiated, prospective, randomized, open-label, multicenter pilot study evaluating selective CRP apheresis as an adjunct to standard of care in patients with infarct-related cardiogenic shock. Patients are randomized to receive either standard therapy alone or standard therapy plus selective CRP apheresis using the PentraSorb®-CRP system.
The primary objective is to assess the effect of CRP apheresis on the CLIP score at 66 ± 8 hours after randomization. Secondary objectives include clinical outcomes, inflammatory biomarkers, and safety endpoints.
Inclusion: Cardiogenic shock complicating acute myocardial infarction with planned revascularization by percutaneous coronary intervention (PCI); Cardiogenic shock defined as:; Systolic blood pressure <90 mmHg for >30 minutes or requirement of catecholamine infusion to maintain systolic blood pressure ≥90 mmHg, and; Signs of impaired organ perfusion (at least one of the following): Cold, clammy skin and extremities, Altered mental status, Oliguria with urine output <30 mL/hour, Arterial lactate >2 mmol/L; C-reactive protein (CRP) level ≥7 mg/L at baseline; Age ≥18 years; Informed consent provided by the participant or, if the participant is unable to consent, inclusion after assessment and documentation of the presumed patient's will by two physicians (one independent), with informed consent obtained as soon as possible.
Exclusion: Life expectancy <12 months prior to cardiogenic shock; Fever (body temperature >38°C) or acute infection with fever within the last 14 days; Chronic inflammatory disease; Known history of severe hepatic failure; Cardiogenic shock due to causes other than acute myocardial infarction; Chronic kidney disease with creatinine clearance <30 mL/min/1.73 m² prior to hospital admission; Age >80 years; Participation in another interventional clinical trial; Pregnancy; Resuscitation duration >30 minutes; Onset of cardiogenic shock >12 hours before randomization.